Navigation Links
DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC

, that its technologies will prove to be safe and effective, that its cash expenditures will not exceed projected levels, that it will be able to obtain future financing or funds when needed, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the U.S. Government or other countries, that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: because orBec® did not achieve statistical significance in its primary endpoint in the pivotal Phase 3 clinical study (i.e. a p-value of less than or equal to 0.05), the Oncologic Drug Advisory Committee ("ODAC") appointed by the FDA voted that the data supporting orBec® did not show substantial evidence of efficacy by a margin of 7 to 2 for the treatment of GI GVHD, although the FDA is not bound by ODAC's decision, the FDA may not consider orBec® approvable based upon existing studies, orBec® may not show therapeutic effect or an acceptable safety profile in future clinical trials, if required, or could take a significantly longer time to gain regulatory approval than DOR expects or may never gain approval; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marke
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:11/21/2014)... MONTREAL , 21. November 2014 ... hat heute bekannt gegeben, dass ... – EMA) die Kennzeichnung als Orphan-Medizinprodukt ... Produktkandidat des Unternehmens zur Behandlung von ... eine seltene, stark beeinträchtigende genetische Krankheit, ...
(Date:11/21/2014)... 20, 2014  Edwards Lifesciences Corporation (NYSE: ... heart valves and hemodynamic monitoring, announced today that it ... support a strong launch of Edwards Lifesciences Foundation,s new ... improve the global communities where its employees live and ... giving will exceed $8 million, including more than $7 ...
(Date:11/21/2014)... BRYDGES, Ontario , Nov. 20, 2014 /PRNewswire/ ... monitor mounting solutions and reading room environment guidance, ... their newest musculoskeletal radiology reading room, which may ... room designs at Penn Medicine. ... by the American College of Radiology,s Imaging 3.0 ...
Breaking Medicine Technology:Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3
... TARRYTOWN, N.Y., April 18, 2012 Bayer HealthCare today ... has cleared its CONTOUR® Next EZ, a new blood ... States.  CONTOUR Next EZ includes an easy-to-use meter and ... new BGM system is being introduced on a market-by-market ...
... launches their Latching Micro-D™ connectors with a new ... quick cable connections to rack and panel equipment.  ... weight, the new latching Micro-D™ connectors, at .050" ... including pull tests that exceeds 100 pound pull ...
Cached Medicine Technology:U.S. FDA Clears Bayer HealthCare's CONTOUR® Next EZ Blood Glucose Monitoring System 2U.S. FDA Clears Bayer HealthCare's CONTOUR® Next EZ Blood Glucose Monitoring System 3Omnetics Launches Panel Mounted Latching Micro-D™ Connectors 2
(Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers are popular ... its new collection of power suppliers. Additionally, it has ... suppliers. All the new models come with big discounts, ... Dec. 20, 2014. , SWAccessControl.com has thousands of happy ... for a long time. It is very wise to ...
(Date:11/23/2014)... Church, VA (PRWEB) November 23, 2014 ... TV Have in Common, **FDAnews On-Demand Webinar**, Dec. 11, ... http://www.fdanews.com/TheFDAisWatchingOnDemand , The FDA’s focus on promotional activities ... , Now they're looking at websites, Twitter, ... Mark the calendar for Thursday, Dec. 11, for On-Demand ...
(Date:11/22/2014)... SC (PRWEB) November 23, 2014 Every ... to their communities. AlignLife experience rapid growth in the ... a very unique opportunity. AlignLife of Simpsonville ... AlignLife offices for their first annual Toy Drive. These ... charity they would support with this year's toy drive. ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 A classic black ... of the most famous dress suppliers, has unveiled its new ... new dresses are now offered at a big discount, up ... special offer. , The new black prom dresses, made ... order to meet the needs of all customers, the company ...
(Date:11/22/2014)... “Due to my knee replacement surgery, I had to ... using the ice grip attachment, I noticed how dangerous the ... be a safer way to prevent possible injuries, so I ... BLOCK offers added safety and stability in slick and icy ... and damage associated with traditional spiked ice grips. As a ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Greenville Area AlignLife Offices Join Together for a Local Toy Drive 2Health News:New Black Prom Dresses from BellasDress.com 2
... , , MISSION VIEJO, Calif., Sept. ... the parent company of the Ensign(TM) group of skilled nursing, rehabilitative ... of Directors has declared a quarterly cash dividend of $0.045 per ... 2009 to shareholders of record as of September 30, 2009. Ensign ...
... BOTHELL, Wash., Sept. 18 SCOLR Pharma, Inc. ... September 15, 2009, the NYSE Amex LLC (the "Exchange") accepted ... disclosed listing deficiency as set forth in Section 1003(a)(iii) of ... Company,s failure to maintain stockholder,s equity of at least $6,000,000 ...
... , , LAWRENCE, Mass., Sept. ... leading manufacturer of innovative dialysis products, today announced that home dialysis ... Road Trip" with the NxStage(R) System One(TM). As a portable ... opportunity to fit hemodialysis therapy into his own lifestyle and schedule. ...
... , , , , ... hip abnormalities, combined with advances in diagnostic imaging techniques and minimally ... chronic, misdiagnosed hip pain. , , Increasingly, ... of degenerative hip disease, get patients back to their chosen activities ...
... , Statement of Andy Stern, President of ... Andy Stern, President of the Service Employees International Union, ... extremists to silence working families by attacking progressive individuals and community ... of profound change for this country -- from kitchen tables to ...
... , , HAYWARD, Calif., Sept. ... global leader in the medical aesthetics market, today announced that it ... on Tuesday, September 29, 2009 at the Grand Hyatt New York ... for 10:30 a.m. Eastern Time on September 29, 2009. Stephen ...
Cached Medicine News:Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 2Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 3Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 4Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 2Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 3Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 2Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 3Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 4Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 5Health News:Working Women and Men Will Not Be Silenced by Right Wing Attack Dogs; SEIU Members and Other Working Americans Will Continue to Speak Out For the America We Believe In 2Health News:Solta Medical to Present at the Maxim Group Growth Conference 2
... VasoSeal VHD was the ... stop bleeding after diagnostic ... radiology procedures. It is ... device approved for immediate ...
... VasoSeal VHD was the ... stop bleeding after diagnostic ... radiology procedures. It is ... device approved for immediate ...
InterVascular HemaCarotid Patch product line offers the vascular surgeon a complete range of knitted, collagen coated patches in a wide range of sizes for carotid endarterectomy and angioplasty witho...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: